Research of the Pharmacokinetics and Pharmacodynamics of Torasemide in the Treatment of Children Patients with Acute Heart Failure / 昆明医科大学学报

ABSTRACT

Objective To investigate the pharmacokinetics and pharmacokinetics of torsemide in children with acute heart failure.Methods Ninety cases of children with acute heart failure patients were randomly divided into three groups which were given different intravenous therapy doses of torsemide. Our goal is to provide the basis for clinical rational therapy by analyzing parameter of the pharmacokinetics and pharmacokinetics of torsemide which is acquired by detecting plasma concentration of torsemide with liquid chromatography and tandem mass spectrometry after a one-time medication. Result Average pharmacokinetic parameters of the three groups in addition to the peak concentration (Cmax) and medication in the area under the curve (AUC0-16) are different (P＜0.01), the rest of the pharmacokinetic parameters had no significant difference (P＞0.05) . The 24 hours urine volume of the experimental groupⅡand the experimental groupⅢwere obviously higher than that of the experimental groupⅠ, so the difference was statistically significant (P＜0.01).The 24 hours urine volumes between the experimental group Ⅱ and the experimental group Ⅲ were no significant difference (P＞ 0.05).There was no significant change in blood pressure, weight, abdominal girth, blood potassium, blood sodium and blood chlorine in the three dose groups compared with those before the treatment. There was no significant difference between the three groups (P＞0.05) . Conclusion The children with acute heart failure were well tolerated with torsemide. The recommended dose of torsemide is 1.0 mg/(kg.d) in the treatment of acute heart failure in children, based on pharmacokinetic and pharmacodynamic characteristics.